Revvity, Inc. (RVTY): Initiation of Coverage (Last 3 Fiscal Years)
Investment Summary
- Strategic Transformation: Revvity has executed a significant portfolio transformation since 2023, divesting non-core businesses and sharpening its focus on Diagnostics, Life Sciences Solutions, and Signals Software. The company is now positioned as a global leader in health sciences, with a growing emphasis on AI-driven software and high-growth diagnostics.
- Financial Performance: Revenue has stabilized and returned to growth after a sharp COVID-related decline in 2023. FY2025 revenue reached $2,856.1M (+4% YoY), with Diagnostics outpacing Life Sciences. Gross and operating margins have faced pressure from tariffs, FX, and product mix, but margin expansion initiatives and cost actions are ongoing.
- Diagnostics Outperformance: Diagnostics, especially Reproductive Health and Immunodiagnostics (ex-China), is the primary growth engine, delivering high single- to double-digit organic growth in 2026 YTD. The company is divesting its China Immunodiagnostics business to reduce exposure to policy risk.
- Software Differentiation: The Signals Software suite is a core differentiator, delivering double-digit APV/ARR growth and supporting overall margin stability. New AI-enabled products are driving incremental demand.
- Capital Allocation: Aggressive share repurchases ($820.8M in FY2025), steady dividends, and disciplined M&A (notably ACD/Labs acquisition) have been key priorities. Free cash flow conversion remains robust (>100% YTD Q2 2026).
- Risks: Ongoing margin compression, China policy/regulatory headwinds, competitive intensity, and execution risk on acquisitions and restructuring.
Business Overview
Revvity, Inc. is a global provider of life sciences and diagnostics solutions, reporting two segments, Life Sciences and Diagnostics, across three main business lines:
- Diagnostics: Immunodiagnostics, reproductive health (notably newborn screening), and applied genomics.
- Life Sciences Solutions: Instruments, reagents, consumables, and specialty pharma services.
- Signals Software: Scientific data platforms (SaaS and on-premises), with deep integration of AI/ML capabilities.
The company serves customers in over 160 countries and employs approximately 11,000 people.
Segment Revenue Mix (FY2025)
| Segment | Revenue ($M) | % of Total |
|---|---|---|
| Life Sciences | 1,431.1 | 50.1% |
| Diagnostics | 1,424.9 | 49.9% |
| Total | 2,856.1 | 100% |
Financial Snapshot: Last 3 Fiscal Years
Key Financial Metrics (Fiscal Year Ended)
| Metric | FY2025 (12/28/2025) | FY2024 (12/29/2024) | FY2023 (12/31/2023) |
|---|---|---|---|
| Revenue ($M) | 2,856.1 | 2,755.0 | 2,750.6 |
| Revenue Growth (%) | +4 | +0.2 | -17.0 |
| Gross Margin (%) | 54.8 | 55.8 | - |
| Operating Income ($M) | 356.6 | 346.7 | 300.6 |
| Operating Margin (%) | 12.5 | 12.6 | 10.9 |
| Net Income ($M) | 241.2 | 270.4 | 693.1 |
| Diluted EPS ($) | 2.07 | 2.20 | 5.55 |
| Free Cash Flow ($M) | 515.4 | 578.3 | - |
| Cash & Equivalents ($M) | 919.9 | 1,163.4 | 913.2 |
| Net Debt ($M) | 2,300.2 | 1,987.1 | 2,237.3 |
| Dividend per Share ($) | 0.28 | 0.28 | 0.28 |
| Shares Repurchased (M) | 8.5 | 3.2 | 3.4 |
| Employees | ~11,000 | ~11,000 | ~11,500 |
Segment Analysis
Diagnostics
| Fiscal Year | Revenue ($M) | YoY Growth (%) | Segment Op. Income ($M) | Segment Margin (%) |
|---|---|---|---|---|
| 2025 | 1,424.9 | +5 | 344.2 | 24.2 |
| 2024 | 1,356.4 | +3 | 353.9 | 26.1 |
| 2023 | 1,292.4 | -11.4 | 298.0 | 23.1 |
- Drivers: Immunodiagnostics and Reproductive Health (notably newborn screening, Genomics England partnership).
- Headwinds: Tariffs, FX, China policy changes (DRG/VBP), global birth rate declines.
- Actions: Divestiture of China Immunodiagnostics business (signed Q2 2026).
Life Sciences
| Fiscal Year | Revenue ($M) | YoY Growth (%) | Segment Op. Income ($M) | Segment Margin (%) |
|---|---|---|---|---|
| 2025 | 1,431.1 | +2 | 458.3 | 32.0 |
| 2024 | 1,398.6 | -3 | 467.3 | 33.4 |
| 2023 | 1,458.2 | +0 | 512.3 | 35.1 |
- Drivers: Software (Signals), reagents growth, AI-driven instrument demand.
- Headwinds: Instrument sales pressured by pharma/biotech budget cuts, academic/government funding uncertainty, FX.
- Actions: Cost containment, supply chain adjustments, increased R&D investment.
Signals Software
- Growth: Double-digit APV/ARR growth, >30% organic growth in Q2 2025, new AI-enabled launches (BioDesign, Xynthetica, LabGistics).
- Volatility: Lumpy organic growth due to contract timing; strong SaaS transition.
- Differentiation: Deep integration with pharma/biotech R&D workflows, AI/ML capabilities.
Key Bullish and Bearish Points
| Bullish Points | Bearish Points |
|---|---|
| Diagnostics segment (esp. Reproductive Health, Immunodiagnostics ex-China) delivering high growth | Margin compression from tariffs, FX, and product mix; gross margin down 104 bps in FY2025 |
| Signals Software suite: double-digit APV/ARR growth, robust innovation pipeline | Persistent policy headwinds in China; divestiture of China Immunodiagnostics required |
| Aggressive capital return: $820.8M buybacks in FY2025, continued in 2026 | Life Sciences Solutions segment saw -3% organic decline in Q2 2026 (software comp drag) |
| Strong free cash flow conversion (>100% YTD Q2 2026) | Academic/government demand still recovering, not yet robust |
| AI-driven demand from both traditional and non-traditional customers accelerating | Guidance assumes no further acceleration in end markets; upside not yet embedded |
| Strategic M&A (ACD/Labs acquisition post-FY2025) | Significant increase in net debt due to aggressive share repurchases |
| Ongoing investment in R&D and digital/software capabilities | Decline in net income and EPS YoY (FY2025 net income $241.2M vs. $270.4M in FY2024) |
Positive and Negative Catalysts
| Positive Catalysts | Negative Catalysts |
|---|---|
| Completion of China Immunodiagnostics divestiture (expected by end of 2027) | Delays or issues in closing China Immunodiagnostics divestiture |
| Continued outperformance in Diagnostics (Reproductive Health, Immunodiagnostics ex-China) | Renewed policy headwinds in China or other key geographies |
| Acceleration in pharma/biotech and academic/government demand, especially AI-driven workflows | Prolonged weakness in Life Sciences Solutions or delayed recovery in academic/government spending |
| Successful ramp and adoption of new Signals software products | Failure of new software launches to gain traction or cannibalization of legacy products |
| Expansion/extension of Genomics England partnership | Loss of major contracts (e.g., Genomics England) or competitive displacement |
| Further operational efficiency gains and cost initiatives | Margin pressure from inflation, supply chain, or reinvestment outpacing revenue growth |
| Additional M&A or tuck-in acquisitions in high-growth adjacencies | Poor integration of acquisitions or overpayment |
